Jci_page_head_homepage_01 Jci_page_head_homepage_02
R. Gisli Jenkins, Xiao Su, George Su, Christopher J. Scotton, Eric Camerer, Geoffrey J. Laurent, George E. Davis, Rachel C. Chambers, Michael A. Matthay, Dean Sheppard
Published in Volume 116, Issue 6
J Clin Invest. 2006; 116(6):1606–1614 doi:10.1172/JCI27183
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2
Stimulation of lung epithelial cells with a PAR1 agonist leads to αv β6 -dependent TGF-β activation.

(A) IMLE cells were cocultured with TML cells and stimulated with increasing doses of SFLLRN, and luciferase activity from the TGF-β–responsive plasminogen activator inhibitor-1 promoter was measured. IMLE cells expressing human WT β6 (black bars) were compared with IMLE cells that had no cell surface β6 (white bars), and both were also stimulated with increasing doses of SFLLRN in the presence of αvβ6 blocking antibody (IMLE β6-positive, dark gray bars; IMLE β6-negative, light gray bars). (B) To determine the proportion of TGF-β expression that was mediated by αvβ6 in epithelial cell cultures, IMLE cells and normal human bronchial epithelial (NHBE) cells were stimulated with 10 μM of SFLLRN (gray bars), in the absence or presence of an αvβ6 blocking antibody (black bars) or a pan–TGF-β blocking antibody (white bars), in coculture with TML cells, and luciferase activity was measured. All experiments were performed in triplicate, and the mean + SEM is shown. Results are a representative example of at least 2 identical independent experiments.